Clinical Trials Browser

Phase 2/3 × INDUSTRY × Capecitabine × Clear all

NCT06926868 2026-03-11

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Phase 2/3 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07413939 2026-03-10

BREnnA

Phase 2/3 Not yet recruiting

HER2-positive Breast Cancer

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Phase 2/3 Not yet recruiting

Gastrointestinal

HER2-positive Gastric Cancer

NCT05980481 2025-09-29

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

Phase 2/3 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT05141721 2025-05-16

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Phase 2/3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05065957 2025-04-30

Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer

Phase 2/3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT03512756 2024-11-06

A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer

Phase 2/3 Terminated

130 enrolled 13 charts

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT02746796 2024-05-03

Study of ONO-4538 in Gastric Cancer

Phase 2/3 Completed

Gastrointestinal

Stomach Neoplasms

NCT03500380 2024-02-20

A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Phase 2/3 Unknown

Breast Diseases, Breast Neoplasms

NCT05976568 2023-08-04

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Phase 2/3 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03873532 2020-02-13

A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients

Phase 2/3 Unknown

Gastrointestinal

Biliary Tract Neoplasms

NCT02213744 2017-01-06

HERMIONE

Phase 2/3 Terminated

Breast Neoplasms